XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue- Gilead Science Inc (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 14, 2022
Jun. 30, 2024
Oct. 31, 2022
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Sep. 30, 2023
Collaboration And Other Agreements [Line Items]                  
Total revenues       $ 72,839,000 $ 110,708,000 $ 108,273,000 $ 130,609,000    
Deferred revenue, current       10,302,000   10,302,000   $ 16,319,000  
Deferred revenue, net of current portion       55,840,000   55,840,000   55,503,000  
Gilead | 2022 Gilead Collaboration And License Agreement                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment     $ 60,000,000            
Total revenues       0 400,000 0 900,000    
Deferred revenue       57,100,000   57,100,000   56,800,000  
Deferred revenue, current       1,300,000   1,300,000   1,300,000  
Deferred revenue, net of current portion       55,800,000   55,800,000   55,500,000  
Potential target nomination, option fees and milestone payments $ 1,700,000,000                
Gilead | Gilead First Research Program                  
Collaboration And Other Agreements [Line Items]                  
Total revenues   $ 3,300,000   0 $ 400,000 11,000,000 $ 2,400,000    
Deferred revenue, current       $ 0   $ 0   $ 11,000,000  
Revenue, remaining performance obligation, amount                 $ 15,700,000
Potential option fees                 $ 10,000,000